• Main Page
• Contacts
• Log In/Submit

---

---

---

---

---

---

---

---

More Results: 1  2  3  4  5  

World IT News

• D-Link Drops Price on Two Best-Selling 802.11n RoutersAggressive Pricing Rounds Out D-Link's Lineup of Wi-Fi Solutions to Offer Industry's Most Competitive Good/Better/Best Solution
• D-Link Offers Aggressive 'Buy One Get One Free' Switch PromotionFOUNTAIN VALLEY, CA--(Marketwire - July 1, 2008) - D-Link, the end-to-end networkingsolutions provider for consumer and business, today announced it isoffering a 'Buy One, Get One Free' promotion on many of its most popularswitches, including models from the award-winning xStackT series,nationwide July 1 through August 31, 2008. The bold D-Link® promotion represents a savings of $699 to $3,999,depending on model, and is available when one unit is purchased at fullprice from distributors and resellers of D-Link solutions. This promotionis ideal for growing businesses looking to expand their network, upgradefrom 10/100 to Gigabit, or for customers looking to add network connectionswhile maintaining a second switch as a hot spare.
• BroadRiver Chooses Egenera for New Hosted Virtualization Products and ServicesEgenera Solutions With vBlade Software Increase Agility and Availability for Competitive Advantage
• FDAAdvisoryCommittee.com to Webcast the FDA Endocrinologic and Metabolic Drugs Advisory Committee Hearing on July 1st & 2nd in Conjunction With TalkPointNEW YORK, NY--(Marketwire - June 30, 2008) - TalkPoint , leading provider of theTools, Technology and Services for Interactive Internet Broadcasting, and FDAAdvisoryCommittee.com , the leadingwebcast and DVD source for FDA Advisory Committee Meetings, today announcedthat TalkPoint will be powering the Endocrinologic and Metabolic DrugsAdvisory Committee Meeting scheduled for July 1st & 2nd. The July Endocrinologic and Metabolic Drugs Advisory Committee Meeting isbeing held to further discuss whether to insist that new diabetes drugshave a positive impact on cardiovascular disease and life span. At issue iswhat benchmarks the FDA should use to approve diabetes drugs. The two-daymeeting of FDA officials and outside medical experts, set to start Tuesday,will discuss whether the agency should require additional, more rigorousbenchmarks, such as proof a drug ultimately lowers risks for cardiovasc
• Labwire Completes First Conversion of USIS BusinessHOUSTON, TX--(Marketwire - June 30, 2008) - Labwire, Inc. ( PINKSHEETS : LBWR ), a leadingprovider of employee screening solutions and canine security andsurveillance services, announced today that it has completed the firstconversion of business under the USIS agreement. "This is a very important accomplishment for us," commented Mr. DexterMorris, Chairman and Chief Executive Officer of Labwire. "Our team workedwell with USIS personnel, and the conversion was completed smoothly and onschedule. We are already planning the next interfaces and data transfersand exploring additional business possibilities with USIS. I am veryexcited about the potential of this strategic relationship."